LifeShare Blood Center deploys Biolog-id’s cutting-edge technology providing digital visibility to convalescent plasma containing antibodies from recovered COVID-19 patients
This aims to assist labs involved with the essential RT-PCR assay part of the “test, trace and isolate” strategy
Highly specific prototype test detects the virus spike protein at clinically relevant concentrations
Our expert webinar series aims to help you get the most from your drug discovery research
Total antibody test aims to deliver superior clinical performance with 100% sensitivity and 99.8% specificity
Watch this on-demand webinar to learn about the applications for cell-based therapies and biologics using advanced high-throughput flow cytometry
The trial will study the use of ruxolitinib, a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients
A rare lung disease drug is being trialed to help fight COVID-19
Advance your COVID-19 research with positive and negative SARS-CoV-2 samples
The study is expected to begin enrolling in June with a target of approximately 450 patients globally
Company to make the device available through broad range of healthcare, state, employer and consumer-initiated channels
The RNAdvance Viral XP is a RNA extraction kit validated for use in infectious disease and real-time PCR virus research
Thermo Scientific Orbitrap Exploris 240 mass spectrometer drives discovery and identification with quantitative precision and accuracy to meet customers' specific analytical requirements
Dr. Ofer Sharon discusses a new cancer research platform designed to improve patient outcomes, cut costs, and minimize unnecessary adverse events
Harnessing the most powerful force in the fight against disease — natural human immunity
The first 4,000 doses have been delivered for use in the Phase 2/3 clinical trial COV002 by the University of Oxford
First patients are expected to be enrolled shortly and additional European regulatory approvals are in process
People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus
Cambridge Cognition has secured over $1.5 million in new contracts to support pharmaceutical clients in delivering virtual clinical trials
